会议:2023 ASH Oral 合作中心:江苏省人民医院 02 ctDNA预测套细胞淋巴瘤奥布替尼+来那度胺+利妥昔单抗疗效及预后 A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis ...
Join us at the 5th European Congress on Cancer and Oncology Research taking place during September 29-30, 2025 at Vienna, Austria and expand your knowledge with the top Oncologists
We are pleased to invite you to read the most viewed papers in 2023 in Cancers (ISSN: 2072-6694) on the topic of clinical research of cancer. The paper list is as follows: “Current Main Topics in Multiple Myeloma”by Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Attilio Olivieri...
Edited byDr. Shu-Heng Jiang 5 February 2024 Exosomes as Emerging Nanoplatform in Cancer Therapy Edited byDr. Ramesh R.C. Gupta,Dr. Farrukh Aqil 13 December 2023 Prostate Cancer Edited byChee Wai Chua,Marianna Kruithof-de Julio 3 November 2022...
We’ll help you find the right home for your research – fast With over 50 journals, including The Lancet Oncology, Cancer Cell, European Journal of Cancer and Cancer Letters, Elsevier’s Oncology Journal Network has the right fit for your paper. ...
Targeting P-selectin enables safer and more effective nanomedicine delivery through caveolin-1-mediated endothelial transcytosis in preclinical medulloblastoma tumour models. Lin Wang Stefan Wilhelm News & Views02 Mar 2023Nature Materials Volume: 22, P: 282-283 ...
TCRT的影响因子整体趋势是比较平稳的,2023年影响因子2.7分,比上一年只有轻微幅度的下降,估计未来的变化也不大,甚至很有可能继续回升。网友分享录取率在80%左右,几乎一投就中。 年发文量 2019年之后,TCRT的年发文量开始上涨,2020年发文量超过了300篇,虽然近三年发文量在200~250篇之间,但有隐隐增长的趋势,发文量...
2002-2023 Information Homepage How to publish in this journal Jennifer.Lovick@sagepub.com Scope Technology in Cancer Research and Treatment (TCRT) is a JCR-ranked, broad-scoped, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and...
Article 29 July 2023 The Cyclin-dependent kinase 1: more than a cell cycle regulator Article Open access 28 October 2023 The two sides of chromosomal instability: drivers and brakes in cancer Article Open access 29 March 2024 References Kops, G. J. P. L., Foltz, D. R. & Clevel...
Updated findings from the study presented during SABCS 2023 showed that at the June 29, 2023, data cutoff, the median PFS in the combination arm (n = 228) was 9.5 months (95% CI, 7.4-10.9) compared with 7.4 months (95% CI, 5.6-8.1) in the placebo arm (HR, 0.76; 95% CI, 0.61...